UBS Downgrades Merck (MRK) to Neutral
More News related to MRK
- Merck (MRK) Delays ProQuad Vaccine Once Again - DJN
- Merc Announces Election of New Director
- Merc Announces Election of New Director
- Go Red For Women(R) and Jennie Garth Ask Women to Speak Up About Their No. 1 Killer
- PROLOR Biotech Reports Merck Receives Final Marketing Authorization in Europe for Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
UBS downgrades Merck (NYSE: MRK) from Buy to Neutral and cuts its price target from $43 to $40.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
